25,100 Shares in Blueprint Medicines Co. (NASDAQ:BPMC) Purchased by Erste Asset Management GmbH

Erste Asset Management GmbH bought a new stake in Blueprint Medicines Co. (NASDAQ:BPMC) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 25,100 shares of the biotechnology company’s stock, valued at approximately $2,323,000.

Several other hedge funds also recently modified their holdings of BPMC. Triad Wealth Partners LLC purchased a new position in shares of Blueprint Medicines during the second quarter valued at approximately $27,000. Covestor Ltd raised its holdings in Blueprint Medicines by 206.7% in the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 403 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Blueprint Medicines during the 3rd quarter worth $108,000. CWM LLC boosted its holdings in shares of Blueprint Medicines by 114.6% during the second quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 590 shares during the last quarter. Finally, Van ECK Associates Corp grew its position in shares of Blueprint Medicines by 13.3% in the second quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $120,000 after purchasing an additional 131 shares during the period.

Blueprint Medicines Stock Up 1.3 %

NASDAQ BPMC opened at $97.62 on Tuesday. The business has a 50 day moving average price of $90.97 and a two-hundred day moving average price of $98.04. Blueprint Medicines Co. has a fifty-two week low of $70.39 and a fifty-two week high of $121.90. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The stock has a market cap of $6.20 billion, a PE ratio of -46.27 and a beta of 0.59.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. During the same period in the prior year, the firm earned ($2.20) earnings per share. The business’s quarterly revenue was up 126.5% compared to the same quarter last year. As a group, sell-side analysts predict that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on BPMC shares. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. JPMorgan Chase & Co. started coverage on shares of Blueprint Medicines in a report on Thursday, November 14th. They set an “overweight” rating and a $126.00 price objective on the stock. Wedbush restated an “outperform” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Thursday, November 14th. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Monday, November 18th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Blueprint Medicines currently has an average rating of “Moderate Buy” and an average target price of $122.11.

Insider Transactions at Blueprint Medicines

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $95.10, for a total transaction of $216,257.40. Following the completion of the transaction, the chief operating officer now directly owns 71,657 shares of the company’s stock, valued at $6,814,580.70. This trade represents a 3.08 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Fouad Namouni sold 3,633 shares of the company’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares in the company, valued at approximately $6,169,332.40. This trade represents a 5.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.21% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.